The commercialisation of StemPrintER and its next generation derivative SPARE, the multi-gene prognostic assay intended for the prediction of risk of recurrence in luminal, ER+/HER2- breast cancer patients.
Multigene prognostic tests can assist decision making on treatments, differentiating low risk patients who could be spared chemotherapy from higher risk patients who might benefit from chemotherapy or prolonged endocrine treatments.Find out more
StemPrintER was developed to be a novel genomic predictor based on 20 stem cell genes. These 20 genes have high expression levels that identify a similar group of patients with negative results from four distinct public breast cancer datasets.Find out more
Dr Kunwar Shailubhai
55 Park Lane
London W1K 1NA